Bioanalytical Systems (NASDAQ:BASI) and US Stem Cell (OTCMKTS:USRM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.
This is a breakdown of recent ratings for Bioanalytical Systems and US Stem Cell, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|US Stem Cell||0||0||0||0||N/A|
Valuation and Earnings
This table compares Bioanalytical Systems and US Stem Cell’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bioanalytical Systems||$26.35 million||0.78||-$190,000.00||N/A||N/A|
|US Stem Cell||$6.70 million||0.85||-$2.16 million||N/A||N/A|
Bioanalytical Systems has higher revenue and earnings than US Stem Cell.
This table compares Bioanalytical Systems and US Stem Cell’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|US Stem Cell||-42.80%||N/A||-147.07%|
Risk & Volatility
Bioanalytical Systems has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, US Stem Cell has a beta of 5.86, suggesting that its share price is 486% more volatile than the S&P 500.
Institutional & Insider Ownership
6.1% of Bioanalytical Systems shares are owned by institutional investors. 7.8% of Bioanalytical Systems shares are owned by company insiders. Comparatively, 16.7% of US Stem Cell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Bioanalytical Systems beats US Stem Cell on 5 of the 9 factors compared between the two stocks.
Bioanalytical Systems Company Profile
Bioanalytical Systems, Inc. provides drug discovery and development services, and analytical instruments for pharmaceutical, biotechnology, academic, and government organizations in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment also provides in vivo sampling services for the continuous monitoring of chemical changes in life; non-clinical and pathology services; analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to measure drug and metabolite concentrations in complex biological matrices; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; and climate-controlled archiving services for its customers' data and samples. The Research Products segment offers analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments; and Vetronics' products, such as instruments and related software to monitor and diagnose cardiac function, and measure other vital physiological parameters in cats and dogs in veterinary clinics. Bioanalytical Systems, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.
US Stem Cell Company Profile
U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.
Receive News & Ratings for Bioanalytical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems and related companies with MarketBeat.com's FREE daily email newsletter.